Clinical trials and biomarker research on lung cancer in China.
BACKGROUND
Over the past 10 years, there have been significant advances in clinical trials and translation research on lung cancer in China. These advances have changed the clinical practice of lung cancer treatment. Translation research has clarified many molecular mechanisms of lung cancer development, growth and metastasis. Based on these results, a few cancer-driving molecular targets were identified. Many new compounds that directly or indirectly target these driver genes have been developed and tested.


METHODS
Studies from the literature and ongoing work from the author's group were reviewed. This was with the aim of outlining the current state of a clinical trial cooperative group for lung cancer and highlighting some important clinical trials and biomarker research that have changed lung cancer clinical practice in China.


CONCLUSIONS
For biomarker-driven clinical research, it is important to identify subgroups of patients who are most likely to benefit from given targeted therapies. In this setting, the rapid identification and translation of validated biomarkers will be integral to the treatment of lung cancer. It is also important to utilize results from high-quality clinical research groups to enrich patients lives and to perform these challenging clinical trials.
Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou 510080, China. syylwu@live.cn
Yi-long
YL
Wu
Qing
Q
Zhou
D014408:Biomarkers, Tumor / Q000235:genetics; D002681:China; D002986:Clinical Trials as Topic; D019363:Cytochrome P-450 CYP1A1 / Q000235:genetics; D066246:ErbB Receptors / Q000037:antagonists & inhibitors / Q000235:genetics; D000077156:Gefitinib; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000401:mortality; D009154:Mutation; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use; D011799:Quinazolines / Q000627:therapeutic use; D057170:Translational Research, Biomedical
D014408:Biomarkers, Tumor; D047428:Protein Kinase Inhibitors; D011799:Quinazolines; C569463:CYP1A1 protein, human; D019363:Cytochrome P-450 CYP1A1; D066246:ErbB Receptors; D000077156:Gefitinib